BioWorld MedTech

April 13, 2016

Atricure probes underpenetrated AF market with latest FDA clearance

Flexibility is the key differentiator of Atricure Inc.'s newest FDA-cleared device. The company launched the Cryoform cryoablation probe in Europe last year under a CE mark and now has an FDA 510(k) clearance for the U.S. market. Read More

Forbion closes third venture fund at $208M; eyes on early stage

PAD awareness still an issue for doctors

ODAC: Rociletinib doesn't rise to the accelerated approval challenge

Singapore zeroes in on med-tech as a viable growth opportunity

Other news to note

Financings

Appointments and advancements

Daily M&A

Product Briefs

Keeping you up to date on recent developments in oncology

Today's news in brief

BioWorld

BioWorld briefs for July 9, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...